Renaissance discloses 5.47% stake in Corcept

Corcept Therapeutics Incorporated received an updated ownership report from investment manager Renaissance Technologies LLC and its parent, Renaissance Technologies Holdings Corporation.

Rhea-AI Filing Summary

Corcept Therapeutics Incorporated received an updated ownership report from investment manager Renaissance Technologies LLC and its parent, Renaissance Technologies Holdings Corporation. As of December 31, 2025, they report beneficial ownership of 5,758,528 shares of Corcept common stock, representing 5.47% of the outstanding class.

Renaissance reports sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing notes that certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds, and states the position is held in the ordinary course of business, not to change or influence control of Corcept.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Corcept Therapeutics (CORT) does Renaissance Technologies report owning?

Renaissance Technologies reports beneficial ownership of 5.47% of Corcept’s common stock. The filing states they hold 5,758,528 shares as of December 31, 2025, crossing the 5% disclosure threshold that requires a Schedule 13G/A ownership report.

How many Corcept Therapeutics (CORT) shares does Renaissance Technologies beneficially own?

Renaissance Technologies reports beneficial ownership of 5,758,528 Corcept shares. The Schedule 13G/A indicates these are common shares with sole voting and dispositive power, held on behalf of certain funds managed by Renaissance Technologies LLC as of December 31, 2025.

Who are the reporting persons in the Corcept Therapeutics (CORT) Schedule 13G/A?

The reporting persons are Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation. Renaissance Technologies LLC is a Delaware limited liability company, and Renaissance Technologies Holdings Corporation is a Delaware corporation, both reporting their beneficial ownership in Corcept’s common stock.

Does Renaissance Technologies have sole or shared voting power over its Corcept (CORT) shares?

Renaissance Technologies reports sole voting power over all 5,758,528 shares. The filing shows zero shared voting power and zero shared dispositive power, indicating full authority by the reporting entities over how these Corcept shares are voted and disposed.

Are Corcept Therapeutics (CORT) shares held by Renaissance to influence control of the company?

The filing states the Corcept shares are held in the ordinary course of business, not to influence control. Renaissance certifies the securities were not acquired and are not held for changing or influencing control of Corcept or in connection with any such transaction.

Which entities benefit economically from Renaissance’s Corcept Therapeutics (CORT) holdings?

Certain funds managed by Renaissance Technologies LLC have rights to dividends and sale proceeds. The Schedule 13G/A explains that these funds, rather than the management company alone, are entitled to receive income and proceeds from the Corcept common stock position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 02:12 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

CORCEPT THERAPEUTICS INCORPORATED

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

218352102

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 218352102

1

Names of Reporting Persons

Renaissance Technologies LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,758,528.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,758,528.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,758,528.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.47 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 218352102

1

Names of Reporting Persons

Renaissance Technologies Holdings Corporation

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,758,528.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,758,528.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,758,528.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.47 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CORCEPT THERAPEUTICS INCORPORATED
(b)	Address of issuer's principal executive offices: 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA 94065
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC").
(b)	Address or principal business office or, if none, residence: 800 Third Avenue New York, New York 10022
(c)	Citizenship: RTC is a Delaware limited liability company, and RTHC is a Delaware corporation.
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.: 218352102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5758528
(b)	Percent of class: 5.47 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5758528
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5758528
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Certain funds managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Renaissance Technologies LLC

Signature:	Brian Felczak
Name/Title:	Chief Financial Officer
Date:	02/12/2026

Renaissance Technologies Holdings Corporation

Signature:	Brian Felczak
Name/Title:	Vice President
Date:	02/12/2026

Exhibit Information

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of Common Stock, $0.001 par value of CORCEPT THERAPEUTICS INCORPORATED.